BR0107703A - Flavivìrus recombinantes e processos para uso dos mesmos - Google Patents

Flavivìrus recombinantes e processos para uso dos mesmos

Info

Publication number
BR0107703A
BR0107703A BR0107703-1A BR0107703A BR0107703A BR 0107703 A BR0107703 A BR 0107703A BR 0107703 A BR0107703 A BR 0107703A BR 0107703 A BR0107703 A BR 0107703A
Authority
BR
Brazil
Prior art keywords
recombinant
exogenous
flaviviruses
nucleic acid
processes
Prior art date
Application number
BR0107703-1A
Other languages
English (en)
Inventor
Raul Andino-Pavlovsky
Andres Mcallister-Moreno
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR0107703A publication Critical patent/BR0107703A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FLAVIVìRUS RECOMBINANTES E PROCESSOS PARA USO DOS MESMOS". A presente invenção provê flavivírus recombinantes, especificamente flavivírus recombinantes que compreendem seq³ências de nucleosídeo exógenos que codificam seq³ências de aminoácido exógenos. Estes vírus de flavivírus recombinantes compreendem um ácido nucléico exógeno. A infecção de uma célula hospedeira com um flavivírus recombinante provê expressão do ácido nucléico exógeno em uma célula hospedeira e produção de um polipetídeo antigênico codificado pelo ácido nucléico exógeno. Tais flavivírus recombinantes são úteis na promoção de uma resposta imune para o polipeptídeo exógeno.
BR0107703-1A 2000-01-21 2001-01-19 Flavivìrus recombinantes e processos para uso dos mesmos BR0107703A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17744900P 2000-01-21 2000-01-21
US09/653,754 US6589531B1 (en) 2000-01-21 2000-09-01 Recombinant yellow fever virus and method of use thereof
PCT/US2001/001866 WO2001053467A1 (en) 2000-01-21 2001-01-19 Recombinant flaviviruses and methods of use thereof

Publications (1)

Publication Number Publication Date
BR0107703A true BR0107703A (pt) 2002-10-15

Family

ID=26873305

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107703-1A BR0107703A (pt) 2000-01-21 2001-01-19 Flavivìrus recombinantes e processos para uso dos mesmos

Country Status (9)

Country Link
US (2) US6589531B1 (pt)
EP (1) EP1250421A1 (pt)
JP (1) JP2003520597A (pt)
CN (1) CN1398297A (pt)
AU (1) AU2965601A (pt)
BR (1) BR0107703A (pt)
CA (1) CA2395855A1 (pt)
MX (1) MXPA02006888A (pt)
WO (1) WO2001053467A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof
US7247619B2 (en) * 2000-05-19 2007-07-24 Univ Leland Stanford Junior Viral vectors useful in induction of humoral or cellular immunity
EP1281767A3 (en) * 2001-07-31 2003-05-28 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of tumors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
CA2467397A1 (en) * 2001-11-26 2003-06-05 Replikun Biotech Pty Ltd Flavivirus vaccine delivery system
US20030228261A1 (en) * 2002-06-05 2003-12-11 Aladar Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
EP1593738A4 (en) * 2003-01-30 2006-05-31 Shanghai Tengen Biomedical Co VIRUSELY PARTICULATE VACCINE WITH RECOMBINANT DENGUEVIRUS REPLICANT AS ITS SUPPORT
WO2005047458A2 (en) 2003-06-18 2005-05-26 Genelux Corporation Modified recombinant vaccina viruses and other microorganisms, uses thereof
EP1526185B1 (en) * 2003-10-22 2012-09-12 Genelux Corporation Use of a microorganism or cell to induce autoimmunization of an organism against a tumor
WO2005040390A1 (en) * 2003-07-21 2005-05-06 Shanghai Tengen Biomedical Co., Ltd. A recombinant vaccine using yellow fever virus as vector
CN1304579C (zh) * 2003-07-21 2007-03-14 上海天甲生物医药有限公司 重组的以黄热病病毒为载体的疫苗
DE60329594D1 (de) 2003-08-14 2009-11-19 Genelux Corp Methode zur Herstellung eines Polypeptides, einer RNA oder einer anderen Verbindung in Tumorgewebe
BRPI0504945B8 (pt) 2005-10-31 2022-08-02 Fundacao Oswaldo Cruz Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
CA2668834C (en) 2006-11-07 2016-10-11 Sanofi Pasteur Biologics Co. Stabilization of vaccines by lyophilization
WO2008150496A2 (en) * 2007-05-31 2008-12-11 Genelux Corporation Assay for sensitivity to chemotherapeutic agents
CA3150333A1 (en) 2009-07-31 2011-02-03 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2731961A4 (en) 2011-07-12 2015-12-09 Us Government IDENTIFICATION OF A WEST NIL VIRUS CD4 T-CELL EPITOPS AND USE THEREOF
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11459619B2 (en) 2016-02-08 2022-10-04 The Johns Hopkins University Handheld nucleic acid-based assay for rapid identification
RU2020132280A (ru) * 2018-03-08 2022-04-11 Кодадженикс Инк. Аттенуированные флавивирусы
CN113874032A (zh) * 2019-05-15 2021-12-31 科达金尼克斯有限公司 减毒的黄热病病毒及其用于癌症治疗的用途
CN110859968A (zh) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 激活对肿瘤的系统免疫反应的基因生物药物
CN120676952A (zh) 2022-07-08 2025-09-19 维罗米梭公司 溶瘤痘苗病毒及其重组病毒和使用方法
CN115957303B (zh) * 2022-08-22 2025-06-06 苏州大学 蛇毒多肽Hc-CATH在制备防治寨卡病毒感染的药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
DE69230316T2 (de) 1991-09-19 2000-07-13 Us Health Chimäre und/oder wachstumsgehemmte flaviviren
US5965124A (en) 1991-12-06 1999-10-12 Whitehead Institute For Biomedical Research Replication-competent recombinant viral vaccines and method of producing same
DE19521705C2 (de) 1995-06-14 1997-10-09 Immuno Ag Immunogenes Konstrukt, Verfahren zu dessen Herstellung und Verwendung als Vakzine
CA2282790C (en) 1997-02-28 2011-04-19 St. Louis University Chimeric flavivirus vaccines
WO1999028487A1 (en) 1997-11-28 1999-06-10 The Crown In The Right Of The Queensland Department Of Health Flavivirus expression and delivery system
US6589531B1 (en) * 2000-01-21 2003-07-08 The Regents Of The University Of California Recombinant yellow fever virus and method of use thereof

Also Published As

Publication number Publication date
US6589531B1 (en) 2003-07-08
CN1398297A (zh) 2003-02-19
US6893643B2 (en) 2005-05-17
US20030157128A1 (en) 2003-08-21
EP1250421A1 (en) 2002-10-23
AU2965601A (en) 2001-07-31
CA2395855A1 (en) 2001-07-26
JP2003520597A (ja) 2003-07-08
WO2001053467A1 (en) 2001-07-26
MXPA02006888A (es) 2004-08-12

Similar Documents

Publication Publication Date Title
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
ES2029171A6 (es) Un procedimiento para preparar un polipeptido virico de hepatitis no a y no b post-transfusional (pt-nanbh)
DK289688D0 (da) Ekspression af proapolipoprotein a-i.
ES2527411T3 (es) Gen que confiere resistencia a Phytophthora infestans (tizón tardío) en solanáceas
BRPI0411363A (pt) seqüências de ácidos nucléicos codificando e composições compreendendo peptìdeo sinal ige e/ou il-15 e processos para uso das mesmas
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
DE69922958D1 (de) Hcv hüllproteine partikel : verwendung für therapeutische impfung
DK1025211T3 (da) Hyaluronansyntasegen og anvendelser deraf
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
EA200401504A1 (ru) Слитый белок из числа регуляторных/вспомогательных белков вич
MXPA05005202A (es) Vacuna.
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
DK0851926T3 (da) Varianter af humant rekombinant gamminterferon (rhu-IFN-gamma) med forøget termisk stabilitet
BR9803960A (pt) Gene de desidrogenase de d-sorbitol.
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
BR0205083A (pt) Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
BR112022026248A2 (pt) Conjugados de citocinas
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]